RecruitingNot ApplicableNCT06505460

Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study


Sponsor

China Medical University Hospital

Enrollment

20 participants

Start Date

Apr 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Freezing of gait (FOG) stands out as a devastating symptom of Parkinson's disease (PD), where patients may become momentarily glued to the ground, rendering them incapable of walking efficiently. The pathogenesis of FOG remains uncertain but is likely attributed to functional perturbations in superficial cortical and deep locomotion regions. FOG tends to manifest more prominently during complex walking, such as turning, than during simple straight forward walking, and the reasons for this phenomenon remain unclear. Unfortunately, effective methods for overcoming this ambulatory issue has yet to be identified, and quantifying paroxysmal gait spells proves challenging with clinical rating alone; thus, a scientific tool is warranted. In this 3-year proposal, the investigators plan to address these challenges comprehensively.


Eligibility

Min Age: 20 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study looks at the brain and body mechanisms behind freezing of gait — a common and dangerous symptom in Parkinson's disease where a person suddenly feels unable to move their feet while walking. It examines both non-invasive brain stimulation (such as focused ultrasound) and deep brain stimulation (DBS surgery) to understand how the brain controls movement and why it freezes. **You may be eligible if...** - You are 20–90 years old with a confirmed Parkinson's disease diagnosis - For focused ultrasound patients: at least one of your main Parkinson's symptoms (slowness, tremor, stiffness) is not well-controlled by medications - For DBS patients: you have had Parkinson's for over 5 years and respond to levodopa - Healthy adults aged 40–80 or young adults aged 21–44 may also participate as controls **You may NOT be eligible if...** - You have advanced heart failure or cancer with distant spread - Your Parkinson's is at its most severe stage (Hoehn and Yahr Stage 5) - You have severe dementia or major depression (for DBS candidates) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETranscranial direct current stimulation

A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.


Locations(1)

China Medical University Hospital/Neuro Depart

Taichung, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06505460


Related Trials